NorthWest Biotherapeutics Inc (NWBO)

[pgsd]

QUESTION: Why (upon granting approval for DCVax) wouldn't MHRA include approval for rGBM as well as nGBM in line with the PIM designated criteria ?

The PIM designation for DCVax-L covers all malignant gliomas, which would include both Glioblastoma multiforme (the most severe grade) as well as less malignant grades. and would include both newly diagnosed and recurrent gliomas
(This is particularly relevant due to the amazing rGBM results as well as for nGBM)

#dcvax #allsolidtumors $nwbo

As we await submission of MHRA License application let us remind ourselves of three huge positives we have supporting the peer-reviewed results:-

1. DCVax was the first drug to be designated by UK Authorities as a " Promising Innovative Medicine… pic.twitter.com/tBohU0WMdA

— Peter Davis (@peter_brit) August 16, 2023

https://knowwhatyouhold.com/t/promising-innovative-medicine-pim/234